SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Renin-Angiotensin-Aldosterone System
This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Sagnella, G. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sagnella, G. A
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Editorial

Practical implications of current natriuretic peptide research

Giuseppe A Sagnella

Blood Pressure Unit, Physiological Medicine, St George's Hospital Medical School, Cranmer Terrace, London, SW17 0RE, UK, g.sagnella@ sghms.ac.uk

Key Words: natriuretic peptides • cardiovascular disease • vasopeptidase inhibitors

References

  • Klahr S., Slatopolsky E. Renal regulation of sodium excretion. Arch Intern Med 1973; 131: 780-91.[Abstract/Free Full Text]
  • de Wardener, HE Clarckson EM Concept of natriuretic hormone. Physiol Rev 1985: 30: 659-745.[Web of Science]
  • Henry JP, Gauer OH, Reeves JL Evidence of the atrial location of receptors influencing urine flow. Circ Res 1956; 4: 85-90.[Abstract/Free Full Text]
  • Jamieson JD, Palade GE Specific granules in atrial muscle cells. J Cell Biol 1964; 23: 151-72.[Abstract/Free Full Text]
  • de Bold AJ Atrial natriuretic factor: a hormone produced by the heart. Science 1985; 30: 767-70.[CrossRef]
  • Sagnella GA, Macgregor GA Atrial natriuretic peptides. Quart J Med 1990; 77: 1001-7.[Medline] [Order article via Infotrieve]
  • Blaine EH Atrial natriuretic factor plays a significant role in body fluid homeostasis. Hypertension 1990; 15: 2-8.[Abstract/Free Full Text]
  • John SWM, Krege JH, Oliver PM et al. Genetic decrease in atrial natriuretic peptide and salt-sensitive hypertension. Science 1995; 267: 679-81.[Abstract/Free Full Text]
  • Lopez MJ,Wong SK, Kishimoto I. et al. Salt resistant hypertension in mice lacking the guanylate cyclase-A receptor for atrial natriuretic peptide. Nature 1995; 378: 65-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Gunning M., Brenner BM Urodilatin: a potent natriuretic peptide of renal origin. Curr Opin Nephrol Hypertens 1993; 2: 857-62.[CrossRef][Medline] [Order article via Infotrieve]
  • Lang CC, Choy AJ, Struthers AD Atrial and brain natriuretic peptides: a dual natriuretic peptide system potentially involved in circulatory homeostasis. Clin Sci 1992; 83: 519-27.[Web of Science][Medline] [Order article via Infotrieve]
  • Barr CS, Rhodes P., Struthers AD C-type natriuretic peptide. Peptides 1996; 17: 1243-51.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Lisy O., Jougasaki M., Heublein DM et al. Renal actions of synthetic dendroaspis natriuretic peptide. Kidney International. 1999; 56:502-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Holmes SJ, Espiner EA, Richards AM, Yandle TG, Frampton C. Renal, endocrine, and haemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab 1993; 76: 91-6.[Abstract]
  • Barnett DB Heart failure. Diagnosis of symptomless left ventricular dysfunction. Lancet 1993; i: 1124-5.
  • McDonagh TA, Morrison CE, Lawrence A. et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 1997; 350:829-833.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • De Marco T., Goldman L. Predicting outcomes in severe heart failure. Circulation 1997; 95: 2597-9.[Free Full Text]
  • Berlowitz DR, Ash AS,Hickey EC et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998; 339:1957-63.[Abstract/Free Full Text]
  • Hobbs FDR. The scale of heart failure: diagnosis and management of issues for primary care. Heart 1999; 82(Suppl iv): iv8-iv10.[Medline] [Order article via Infotrieve]
  • Nakao K., OgawaY., Suga S., Imura H. Molecular biology and biochemistry of the natriuretic peptide system I: natriuretic peptides. J Hypertens 1992; 10: 907-12.[Web of Science][Medline] [Order article via Infotrieve]
  • Itoh H., Nakao K., SugawaraA. et al. Gamma-atrial natriuretic polypeptide (gamma ANP)-derived peptides in human plasma: cosecretion of N-terminal gamma ANP fragment and alpha ANP. J Clin Endocrinol Metab 1988;67: 429-37.[Abstract/Free Full Text]
  • Kambayashi Y., Nakao K., Mukoyama M. et al. Isolation and sequence determination of human brain natriuretic peptide in human atrium. FEBS Lett 1990; 259: 341-45.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Richards AM Human plasma atrial natriuretic peptide concentrations in health and disease. Curr Opin Cardiol 1987; 2: 660-70.
  • Sundsfjord JA, Thibault G., Larochelle P., Cantin M. Identification and plasma concentrations of the N-terminal fragment of proatrial natriuretic factor in man. J Clin Endocrinol Metab 1988;66:605-10.[Abstract/Free Full Text]
  • Buckley MG, Sagnella GA, Markandu ND, Singer DRJ, MacGregor GA Concentrations of N-terminal Pro ANP in human plasma: evidence for Pro ANP (1-98) as the circulating form. Clin Chim Acta 1990; 191: 1-14.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Azizi C., Maistre G., Kalotka H. et al. Plasma levels and molecular forms of proatrial natriuretic peptides in healthy subjects and in patients with congestive heart failure. J Endocrinol 1996;148:51-7.[Abstract/Free Full Text]
  • Mukoyama M., Nakao K., Hosoda K. et al. Brain natriuretic peptide as a novel cardiac hormone in humans. J Clin Invest 1991; 87: 1402-12.[Web of Science][Medline] [Order article via Infotrieve]
  • Yasue H., Yoshimura M., Sumida H. et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994;90:195-203.[Abstract/Free Full Text]
  • Buckley MG, Sethi D., Markandu ND, Sagnella GA, Singer DR, MacGregor GA Plasma concentrations and comparisons of brain natriuretic peptide and atrial natriuretic peptide in normal subjects, cardiac transplant recipients and patients with dialysis-independent or dialysis-dependent chronic renal failure. Clin Sci 1992;83:437-44.[Web of Science][Medline] [Order article via Infotrieve]
  • Kohno M., Horio T.,Yokokawa K. et al. Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med 1992; 92: 29-34.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Yandle TG, Richards AM, Gilbert A., Fisher S., Holmes S., Espiner EA Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure. J Clin Endocrinol Metab 1993;76:832-8.[Abstract]
  • Jensen KT, Carstens J., Ivarsen P., Pedersen EB A new, fast and reliable radioimmunossay of brain natriuretic peptide in human plasma. Reference values in healthy subjects and in patients with different diseases. Scand J Clin Lab Invest 1997;57: 529-40.[Web of Science][Medline] [Order article via Infotrieve]
  • Buckley MG, Markandu ND, Miller MA, Sagnella GA, MacGregor GA Plasma concentrations and comparisons of brain and atrial natriuretic peptide in normal subjects and in patients with essential hypertension. J Human Hypertens 1993;7:245-50.[Web of Science][Medline] [Order article via Infotrieve]
  • Hunt PJ, Yandle TG, Nicholls MG, Richards AM, Espiner EA The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma. Biochem Biophys Res Commun 1995;214:1175-83.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA Immunoreactive amino-terminal pro-brain natriuretic peptide(NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol 1997; 47: 287-96.[CrossRef][Medline] [Order article via Infotrieve]
  • Togashi T., Fujita S., Kurosawa T., Hasegawa N., Kikawada R., Kawakami M. Circulating forms of B-type natriuretic peptide after acute myocardial infarction. Clin Chem 1993; 39: 550-1.[Free Full Text]
  • Togashi K., Kameya T., Ando K., Maruma F., Kawakami M. Brain natriuretic peptides in human plasma, spinal cord and cerebrospinal fluid. Clin Chim Acta 1991; 201: 193-200.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hasegawa K., Fujiwara H., Doyama K. et al. Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy. Circulation 1993;88:372-80.[Abstract/Free Full Text]
  • Morita E.,Yasue H.,Yoshimura M. et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 1993; 88: 82-91.[Abstract/Free Full Text]
  • Nishikimi T., Yoshihara F., Morimoto A. et al. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 1996:28: 22-30.[Abstract/Free Full Text]
  • Feldschuh J. Blood volume measurements in hypertensive disease. In: Hypertension, Pathophysiology, Diagnosis and Treatment. Laragh JH and Brenner BM (Eds). Raven Press: New York 1990: 339-47.
  • London GM, Safar ME, Safar AL, Simon AC Blood pressure in the 'low-pressure system' and cardiac performance in essential hypertension. J Hypertens 1985; 3: 337-42.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Haug C., MetzeleA, Kochs M., Hombach V., Grunert A. Plasma brain natriuretic peptide and atrial natriuretic peptide concentrations correlate with left ventricular end-diastolic pressure. Clinical Cardiology 1993;16:553-7.[Web of Science][Medline] [Order article via Infotrieve]
  • Yamamoto K., Burnet JC Jr, Jougasaki M. et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996; 28: 998-4
  • Davidson NC, Naas AA, Hanson JK, Kennedy NS, Coutie WJ, Struthers AD Comparison of atrial natriuretic peptide B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction.Am J Cardiol 1996;77:828-31.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Yamada Y., Goto J.,Yokoto M. Brain natriuretic peptide is a sensitive indicator of impaired left-ventricular function in elderly patients with cardiovascular disease. Cardiology 1997;88: 401-7.[Web of Science][Medline] [Order article via Infotrieve]
  • Lang CC, Prasad N., McAlpine H. et al. Increased plasma levels of brain natriuretic peptide in patients with isolated diastolic dysfunction. Am Heart J 1994; 127: 1635-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Francis GS, Benedict C., Johnston De et al. Comparison of neurodendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. Circulation 1990; 82: 1724-9.[Abstract/Free Full Text]
  • Lerman A., Gibbons R., Rodeheffer, Bailey K, McKinley L., Heublein D. et al. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet 1993; 341: 1105-13.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Omland T.,Aakvaag A.,Vik-Mo H. Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment. Heart 1996; 76: 232-7.[Abstract/Free Full Text]
  • Muders F., Kromer EP, Griese DP et al. Evaluation of plasma natriuretic peptides as markers for left ventricular dysfunction. Am Heart J 1997; 134: 442-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Cowie MC, Struthers AD, Wood DA et al. Value of natriuretic peptides in assesment of patients with possible new heart failure in primary care. Lancet 1997; 350: 1347-51.
  • McDonagh TA, Robb SD, Murdoch DR et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998; 351:9-13.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Luchner A., Burnett Jr, JC, Jougasaki M. et al. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens 2000; 18: 1121-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Gottlieb SS, Kukin ML, Ahern D., Packer M. Prognostic importance of atrial natriuretic peptide in patients with chronic heat failure. JAm Coll Cardiol 1989; 13: 1534-9.[Abstract]
  • WallenT., Landahal S., HednerT. et al.Atrial natriuretic peptides predict mortality in the elderly. J Intern Med 1997; 241: 269-75.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Sayama H., Makamura Y., Saito N., Kinoshita M. Why is the concentration of plasma brain natriuretic peptide in elderly inpatients greater than normal? Coron Artery Dis 1999; 10: 537-40.[Web of Science][Medline] [Order article via Infotrieve]
  • Horio T., Shimada K., Kohno M. et al. Serial changes in atrial and brain natriuretic peptides in patients with acute myocardial infarction treated with early coronary angioplasty. Am Heart J 1993;126:293-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Arakawa N., Nakamura M.,Aoki H., Hiramori K. Relationship between plasma level of brain natriuretic peptide and myocardial infarct size. Cardiology 1994;85:334-40.[Web of Science][Medline] [Order article via Infotrieve]
  • Naruse M.,Takeyama Y.,Tanabe A. et al.Atrial and brain natriuretic peptides in cardiovascular diseases. Hypertension 1994;23: 1231-4.
  • OmlandT, Bonarjee VV, Nilsen DW et al. Prognostic significance of N-terminal pro-atrial natriuretic factor (1-98) in acute myocardial infarction: comparison with atrial natriuretic factor (99-126) and clinical evaluation. Br Heart J 1993;70:409-14.[Abstract/Free Full Text]
  • Hall C., Rouleau JL, Moye L. et al. N-Terminal proatrial natriuretic factor - an independent predictor of long term prognosis after myocardial infarction. Circulation 1994; 89: 1934-42.[Abstract/Free Full Text]
  • Darbar D., Davidson NC, Gillespie N. et al. Diagnostic value of B-type natriuretic peptide concentrations in patients with acute myocardial infarction. Am JCardiol 1996; 78: 284-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Omland T., Aakvaag A., Bonarjee VV et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996;93:1963-9.[Abstract/Free Full Text]
  • Richards AM, Nicholls MG, Yandle TG et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998;97: 1921-9.[Abstract/Free Full Text]
  • Tsutamoto T., Wada A., Maedo K. et al.Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure. Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96:509-16.[Abstract/Free Full Text]
  • Yu CM, Sanderson JE Plasma brain natriuretic peptide- an independent predictor of cardiovascular mortality in acute heart failure. Eur J Heart Failure 1999; 1: 59-65.[Abstract/Free Full Text]
  • Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AMTreatment of heart failure guided by plasma aminoterminal brain natriuretic peptide(N-BNP) concentrations. Lancet 2000: 355: 1126-30.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Murdoch DR, Byrne J., Morton JJ et al. Brain natriuretic peptide is stable in whole blood and can be measured using a simple rapid assay: implications for clinical practice. Heart 1997; 78: 594-7.[Abstract/Free Full Text]
  • Clerico A., Iervasi G., Del Chicca MG, Emdin M., Maffei S., Nannipieri M. et al. Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immuno- radiometric assays in normal subjects and in patients with different degrees of heart failure. J Endocrinol Invest 1998;21:170-9.[Web of Science][Medline] [Order article via Infotrieve]
  • Buckley MG, Marcus NJ,Yacoub MH, Singer DR Prolonged stability of brain natriuretic peptide: importance for non-invasive assessment of cardiac function in clinical practice. Clin Sci 1998;95:235-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Wieczorek SJ, Bailly KR,Thomas P. et al. Clinical evaluation of the triage B-type natriuretic peptide assay for point of care testing of patients with congestive heart failure. Clin Chem 2000; 46:A77(Abstract).
  • Chinkers M., Garbers DL, Chang MS et al. A membrane form of guanylate cyclase is an atrial natriuretic peptide receptor. Nature 1989;338:78-83.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Nakao K., Ogawa Y., Suga S.-I, Imura H. Molecular biology and biochemistry of the natriuretic peptide system.II: Natriuretic peptide receptors. J Hypertens 1992;10:1111-4.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Koller KJ, Goeddel DV Molecular biology of the natriuretic peptides and their receptors. Circulation 1992;86:1081-8.[Abstract/Free Full Text]
  • Anand-Srivastava MBAtrial natriuretic peptide-C receptor and membrane signalling in hypertension. J Hypertens 1997; 15: 815-26.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Maack T., Nikonova LN, Friedman O., Cohen D. Functional properties and dynamics of natriuretic peptide receptors. Proc Soc Exp Biol Med 1996;213:109-16.[CrossRef][Medline] [Order article via Infotrieve]
  • Matsukawa N., Grzesik WJ,Takahashi N. et al.The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. Proc Natl Acad Sci (USA). 1999; 96: 7403-8.[Abstract/Free Full Text]
  • Mukaddam-Daher S., Lambert C., Gutkowska J. Clonidine and ST-91 may activate imidazoline binding sites in the heart to release atrial natriuretic peptide. Hypertension 1997; 30: 83-7. 80. Wilkins MR, Settle SL, Needleman P. Augmentation of the natriuretic activity of exogenous and endogenous atriopeptide in rats by inhibition of cyclic GMP degradation. J Clin Invest 1990;85:1274-9.[Web of Science][Medline] [Order article via Infotrieve]
  • Masanori F., Wada A., Tsumato T., Ohnishi M., Sawaki M. Prevention of cyclic GMP breakdown can enhance the effects of endogenous natriuretic peptides in heart failure. Circulation 1999; 100: 1439(Abstract).
  • Maack T., Suzuki M., Almeida FA, Nussenzweig D., Scarborough RM et al. Physiological role of silent receptors of atrial natriuretic factor. Science 1987; 238: 675-8.[Abstract/Free Full Text]
  • Wei CM, Kim CH, Miller VM, Burnett JCJ. Vasonatrin peptide: a unique synthetic natriuretic and vasorelaxing peptide. J Clin Invest 1993;92:2048-52.[Web of Science][Medline] [Order article via Infotrieve]
  • Jin H., Li B., Cunningham B. et al. Novel analog of atrial natriuretic peptide selective for receptor-A produces increased diuresis and natriuresis in rats. J Clin Invest 1996;98:969-76. 85. Tan Acitl, Russel FG, Thien T., Benraad, TJ Atrial natriuretic peptide.An overview of clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 1993; 24: 28-45.[Web of Science][Medline] [Order article via Infotrieve]
  • Hirschberg R. Biologically active peptides in acute renal failure: recent clinical trials. Nephrol Dial Transplant 1997;12:1563-6.[Free Full Text]
  • Lewis J., Salem MM, Chertow GM et al. Atrial natriuretic factor in oliguric acute renal failure. Anaritide Acute Renal Failure Study Group. Am J Kidney Dis 2000;36:767-74.[Web of Science][Medline] [Order article via Infotrieve]
  • Meyer M., Uberbacher HJ, Bohm E., Schope KB, Brett W., Forssmann WG Ularitide: from renal natriuretic peptide to clinical trials. Curr Opin Nephrol Hypertens 1996;5:364-8.[CrossRef][Medline] [Order article via Infotrieve]
  • Lee LS, Hart D., Packer M. et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure.A double-blind, placebo-controlled, randomized crossover trial. Circulation. 1996;94:3184-9.[Abstract/Free Full Text]
  • Colucci WS, Elkayam U., Horton DP et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000;343:246-53.[Abstract/Free Full Text]
  • Mills RM, LeJemtel TH, Horton DP et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group.JAm Coll Cardiol 1999;34:155-62.[Abstract/Free Full Text]
  • Grines CL Safety and effectiveness of dofetilide for conversion of atrial fibrillation and nesiritide for acute decompensation of heart failure: a report from the cardiovascular and renal advisory panel of the Food and Drug Administration. Circulation 2000;101:E200-E201.[Web of Science][Medline] [Order article via Infotrieve]
  • Roques BP, Noble F., Dauge V., Fournie-Zaluski MC, BeaumontA. Neutral endopeptidase 24.11: structure, inhibition and experimental clinical pharmacology. Pharmac Rev 1993; 45:87-146.[Web of Science][Medline] [Order article via Infotrieve]
  • Rademaker MT, Charles CJ, Espiner EA et al. Neutral endopeptidase inhibition: augmented atrial and brain natriuretic peptide, haemodynamic and natriuretic responses in ovine heart faiulure. Clin Sci 1996; 91: 283-91.[Web of Science][Medline] [Order article via Infotrieve]
  • Erdos EG, Skidgel RA Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J 1989;3:145-51.[Abstract]
  • Roques BP, Beaumont A. Neutral endopeptidase-24.11 inhibitors: from analgesics to antihypertensives? TIPS 1990; 11: 245-9.[Medline] [Order article via Infotrieve]
  • Wilkins MR, Unwin RJ, Kenny AJ Endopeptidase-24.11 and its inhibitors: Potential therapeutic agents for edematous disorders and hypertension. Kidney International 1993;43:273-285. 98. Richards M., Espiner E., Frampton C. et al. Inhibition of endopeptidase EC 24.11 in humans. Renal and endocrine effects. Hypertension. 1990;16:269-76.[Abstract/Free Full Text]
  • O'Connell JE, Jardine AG, Davies DL, McQueen J., Connell JM Renal and hormonal effects of chronic inhibition of neutral endopeptidase (EC 3.4.24.11) in normal man. Clin Sci 1993;85:19-26.[Web of Science][Medline] [Order article via Infotrieve]
  • Sagnella GA, Markandu ND, Buckley MG et al. Hormonal and renal responses to neutral endopeptidase inhibition in normal humans on a low and on a high sodium intake. Eur J Clin Invest 1995;25:165-70.[Web of Science][Medline] [Order article via Infotrieve]
  • Singer DR, Markandu ND, Buckley MG, Miller MA, Sagnella GA, MacGregor GA Dietary sodium and inhibition of neutral endopeptidase 24.11 in essential hypertension. Hypertension 1991;18:798-804.[Abstract/Free Full Text]
  • Bevan EG, Connell JM, Doyle J. et al. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens 1992;10:607-13.[Web of Science][Medline] [Order article via Infotrieve]
  • Richards AM, Wittert GA, Espiner EA, Yandle TG, Ikram H., Frampton C. Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers. Circ Res 1992;71:1501-7.[Abstract/Free Full Text]
  • Richards AM, Wittert GA, Crozier IG et al. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertens 1993;11:407-16.[Web of Science][Medline] [Order article via Infotrieve]
  • Kosoglou T., Herron JM, Chen R., Given BD, Sybertz EJ, Affrime MB Antihypertensive effects of the atriopeptidase inhibitor SCH24826 in essential hypertension. Circulation 1990; 82(suppl 3): 554(Abstract).
  • Elsner D., Muntze A., Kromer EP, Riegger GA Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure. Am J Cardiol 1992;70:494-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Newby DE, McDonagh T., Currie PF, Northridge DB, Boon NA, Dargie HJ Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition. Eur Heart J 1998;19:1808-13.[Abstract/Free Full Text]
  • Northridge DB, Newby DE, Rooney E., Norrie J., Dargie HJ Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure. Am Heart J 1999;138:1149-57.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • WestheimAS, Bostrom P., Christensen CC, Parikka H., Rykke EO, Toivonen L. Hemodynamic and neuroendocrine effects for candoxatril and frusemide in mild stable chronic heart failure. J Am Coll Cardiol 1999;34:1794-801.[Abstract/Free Full Text]
  • Cleland JG, Swedberg K. Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. Lancet 1998; 351:1657-8.[Web of Science][Medline] [Order article via Infotrieve]
  • Taal MW, Brenner BM Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney International 2000; 57: 1803-17.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Margulies KB, Perrella MA, McKinley LJ, Burnett JC, Jr. Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure. J Clin Invest 1991;88:1636-42.[Web of Science][Medline] [Order article via Infotrieve]
  • Seymour AA, Swerdel JN, Abboa-Offei B. Antihypertensive activity during inhibition of neutral endopeptidase and angiotensin converting enzyme. J Cardiovasc Pharmacol 1991;17:456-65.[Web of Science][Medline] [Order article via Infotrieve]
  • Pham I., Gonzalez W., el Amrani AI et al. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension. J Pharmacol Exp Ther. 1993;265:1339-47.[Abstract/Free Full Text]
  • Seymour AA, Asaad MM, Lanoce VM, Langenbacher KM, Fennell SA, Rogers WL Systemic hemodynamics, renal function and hormonal levels during inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in conscious dogs with pacing-induced heart failure. J Pharmacol Exp Ther 1993;266:872-83.[Abstract/Free Full Text]
  • Stergiou GS, Hannah JA, Bevan EG et al. Combined atriopeptidase inhibition and angiotensin converting enzyme inhibition in hypertensive patients (Abstract). J Hypertens 1994;12:1310-1.
  • Favrat B., Burnier M., Nussberger J. et al. Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension. J Hypertens 1995;13:797-804.[Web of Science][Medline] [Order article via Infotrieve]
  • Gros C., Noel N., Souque A. et al. Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): rational design, properties, and potential cardiovascular applications of glycopril and alatriopril. Proc Natl Acad Sci USA 1991;88:4210-4.[Abstract/Free Full Text]
  • French JF, Flynn GA, Giroux EL et al. Characterization of a dual inhibitor of angiotensin I-converting enzyme and neutral endopeptidase. J Pharmacol Exp Ther 1994;268:180-6.[Abstract/Free Full Text]
  • Gonzalez Vera W., Fournie-Zaluski MC, Pham I., Laboulandine I., Roques BP, Michel JB Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats. J Pharmacol Exp Ther 1995;272:343-51.[Abstract/Free Full Text]
  • Robl JA, Sun CQ, Stevenson J. et al. Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase.JMed Chem 1997;40:1570-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Chatelain RE, Ghai RD, Trapani AJ et al. Antihypertensive and natriuretic effects of CGS 30440, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11. J Pharmacol Exp Ther 1998;284:974-82.[Abstract/Free Full Text]
  • Trippodo NC, Robl JA, Asaad MM, Fox M., Panchal BC, Schaeffer TR Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am J Hypertens 1998;11: 363-72.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Trippodo NC, Fox M., Monticello TM, Panchal BC, Asaad MM Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril. J Cardiovasc Pharmacol 1999;34:782-90.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Troughton RW, Rademaker MT, Powell JD et al. Beneficial renal and hemodynamic effects of omapatrilat in mild and severe heart failure. Am J Hypertens 2000;13:1110-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Lainchbury JG, Burnett Jr JC The cardiac hormone atrial natriuretic peptide mediates hemodynamic actions of dual enzyme inhibition in early left ventricular dysfunction (Abstract). Circulation 1999;100:I-438.
  • Raut R., Rouleau JL, Blais CJ et al. Bradykinin metabolism in the postinfarcted rat heart: role of ACE and neutral endopeptidase 24.11. Am J Physiol 1999;276:H1769-79.[Web of Science][Medline] [Order article via Infotrieve]
  • Rousso P., Buclin T., Nussberger J. et al. Effects of a dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100.20, on endocrine and renal functions in healthy volunteers. J Hypertens 1999; 17: 427-37.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Wallis EJ, Ramsay LE, Hettiarachchi J. Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension.Clin Pharmacol Ther 1998;64:439-49.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Norton GR, Woodiwiss AJ, Hartford C. et al. Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects. Am J Hypertens 1999;12:563-71.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Black HR, Chang PI, Reevers RA, Cooper W., Pouleur H. Monotherapy treatment success rate of omapatrilat, a vasopeptidase inhibitor, compared with lisinopril and amlodipine in mild to moderate hypertension. Am J Hypertens 1999;12:26A (Abstract).
  • Zusman R.,Atlas S., Kochlar M.,Adler E., Levy E. Efficacy and safety of omapatrilat, a vasopeptidase inhibitor. Am J Hypertens 1999;12:125A (Abstract).
  • Neutel J., Shepherd A., Pool J., Levy E., Saini R., Chang PI Antihypertensive efficay of omapatrilat, a vasopeptidase inhibitor, compared with lisonopril. Am J Hypertens 1999; 12:124A (Abstract).
  • Lainchbury JG, Richards AM, Nicholls MG, Espiner EA, Yandle TG Brain natriuretic peptide and neutral endopeptidase inhibition in left ventricular impairment. J Clin Endocrin Metab 1999;84:723-9.[Abstract/Free Full Text]
  • McClean DR, Ikram H., Garlick AH, Richards AM, Nicholls MG, Crozier IG The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. J Am Coll Cardiol 2000;36:479-86.[Abstract/Free Full Text]
  • Rouleau JL, Pfeffer MA, Stewart DJ et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000;356:615-20.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hillege HL, Girbes ARJ, De Kam PJ et al. Renal function, neurohormonal activation and survival in patients with chronic heart failure. Circulation 2000;102:203-10.[Abstract/Free Full Text]
  • Messerli FH, Nussberger J. Vasopeptidase inhibition and angio-oedema. Lancet 2000;356:615-20.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 1, No. 4, 304-315 (2000)
DOI: 10.3317/jraas.2000.059
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Sagnella, G. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sagnella, G. A
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement